Kura Oncology, Inc. (KURA)
USD 5.86
(-5.02%)
USD 5.86
(-5.02%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 448.93 Million USD | -1.62% |
| 2022 | 456.3 Million USD | -14.56% |
| 2021 | 534.05 Million USD | -17.48% |
| 2020 | 647.21 Million USD | 167.47% |
| 2019 | 241.97 Million USD | 32.68% |
| 2018 | 182.37 Million USD | 90.27% |
| 2017 | 95.85 Million USD | 37.28% |
| 2016 | 69.82 Million USD | -19.98% |
| 2015 | 87.25 Million USD | 6232.29% |
| 2014 | 1.37 Million USD | 15096.29% |
| 2013 | 9068.00 USD | 9.23% |
| 2012 | 8302.00 USD | 23.54% |
| 2011 | 6720.00 USD | -77.14% |
| 2010 | 29.39 Thousand USD | 125.84% |
| 2009 | 13.01 Thousand USD | 73.38% |
| 2008 | 7508.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 515.11 Million USD | -7.0% |
| 2024 Q1 | 553.9 Million USD | 23.38% |
| 2023 Q3 | 473.77 Million USD | -4.24% |
| 2023 Q2 | 494.73 Million USD | 16.14% |
| 2023 Q1 | 425.97 Million USD | -6.65% |
| 2023 Q4 | 448.93 Million USD | -5.24% |
| 2023 FY | 448.93 Million USD | -1.62% |
| 2022 Q3 | 447.98 Million USD | -4.97% |
| 2022 FY | 456.3 Million USD | -14.56% |
| 2022 Q1 | 498.58 Million USD | -6.64% |
| 2022 Q2 | 471.42 Million USD | -5.45% |
| 2022 Q4 | 456.3 Million USD | 1.86% |
| 2021 Q3 | 561.14 Million USD | -4.06% |
| 2021 Q1 | 620.26 Million USD | -4.16% |
| 2021 Q2 | 584.89 Million USD | -5.7% |
| 2021 Q4 | 534.05 Million USD | -4.83% |
| 2021 FY | 534.05 Million USD | -17.48% |
| 2020 Q1 | 226.46 Million USD | -6.41% |
| 2020 Q2 | 353 Million USD | 55.88% |
| 2020 Q3 | 339.56 Million USD | -3.81% |
| 2020 Q4 | 647.21 Million USD | 90.6% |
| 2020 FY | 647.21 Million USD | 167.47% |
| 2019 Q2 | 265.68 Million USD | 56.64% |
| 2019 Q3 | 254.6 Million USD | -4.17% |
| 2019 FY | 241.97 Million USD | 32.68% |
| 2019 Q1 | 169.61 Million USD | -7.0% |
| 2019 Q4 | 241.97 Million USD | -4.96% |
| 2018 Q3 | 191.5 Million USD | 47.73% |
| 2018 Q4 | 182.37 Million USD | -4.76% |
| 2018 Q2 | 129.62 Million USD | -8.36% |
| 2018 Q1 | 141.45 Million USD | 47.58% |
| 2018 FY | 182.37 Million USD | 90.27% |
| 2017 Q2 | 55.84 Million USD | -9.81% |
| 2017 Q3 | 103.11 Million USD | 84.64% |
| 2017 Q1 | 61.91 Million USD | -11.32% |
| 2017 Q4 | 95.85 Million USD | -7.04% |
| 2017 FY | 95.85 Million USD | 37.28% |
| 2016 Q2 | 81.74 Million USD | 1.69% |
| 2016 FY | 69.82 Million USD | -19.98% |
| 2016 Q4 | 69.82 Million USD | -8.5% |
| 2016 Q3 | 76.3 Million USD | -6.65% |
| 2016 Q1 | 80.38 Million USD | -7.88% |
| 2015 Q3 | 42.82 Million USD | -9.9% |
| 2015 Q4 | 87.25 Million USD | 103.75% |
| 2015 FY | 87.25 Million USD | 6232.29% |
| 2015 Q1 | 54.81 Million USD | 976490.06% |
| 2015 Q2 | 47.53 Million USD | -13.29% |
| 2014 Q3 | 18.21 Thousand USD | 270.41% |
| 2014 FY | 1.37 Million USD | 15096.29% |
| 2014 Q1 | 6793.00 USD | -25.09% |
| 2014 Q2 | 4918.00 USD | -27.6% |
| 2014 Q4 | 5613.00 USD | -69.19% |
| 2013 Q4 | 9068.00 USD | -39.36% |
| 2013 FY | 9068.00 USD | 9.23% |
| 2013 Q3 | 14.95 Thousand USD | -20.05% |
| 2013 Q2 | 18.7 Thousand USD | 364.61% |
| 2013 Q1 | 4026.00 USD | -51.51% |
| 2012 Q3 | 11.46 Thousand USD | -27.14% |
| 2012 FY | 8302.00 USD | 23.54% |
| 2012 Q1 | 24.36 Thousand USD | 262.62% |
| 2012 Q4 | 8302.00 USD | -27.56% |
| 2012 Q2 | 15.73 Thousand USD | -35.44% |
| 2011 Q3 | 10.53 Thousand USD | -32.09% |
| 2011 FY | 6720.00 USD | -77.14% |
| 2011 Q1 | 25.25 Thousand USD | -14.08% |
| 2011 Q2 | 15.5 Thousand USD | -38.62% |
| 2011 Q4 | 6720.00 USD | -36.18% |
| 2010 Q1 | 10.99 Thousand USD | 0.0% |
| 2010 Q3 | 6004.00 USD | -47.26% |
| 2010 Q2 | 11.38 Thousand USD | 3.55% |
| 2010 FY | 29.39 Thousand USD | 125.84% |
| 2010 Q4 | 29.39 Thousand USD | 389.64% |
| 2009 Q1 | 7408.00 USD | -1.33% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q3 | 16.03 Thousand USD | -24.65% |
| 2009 Q2 | 21.27 Thousand USD | 187.19% |
| 2009 FY | 13.01 Thousand USD | 73.38% |
| 2008 Q4 | 7508.00 USD | -38.88% |
| 2008 Q2 | 16.69 Thousand USD | -40.24% |
| 2008 Q1 | 27.93 Thousand USD | 0.0% |
| 2008 FY | 7508.00 USD | 0.0% |
| 2008 Q3 | 12.28 Thousand USD | -26.43% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 69.832% |
| Alkermes plc | 2.13 Billion USD | 78.985% |
| Agenus Inc. | 313.91 Million USD | -43.013% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 88.278% |
| Aptorum Group Limited | 20.64 Million USD | -2075.063% |
| Ardelyx, Inc. | 297.57 Million USD | -50.862% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 41.358% |
| Bicycle Therapeutics plc | 595.34 Million USD | 24.592% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -509.122% |
| ChromaDex Corporation | 54.96 Million USD | -716.78% |
| Chimerix, Inc. | 212.77 Million USD | -110.991% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1487.892% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -1.807% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 79.865% |
| Precision BioSciences, Inc. | 159.78 Million USD | -180.969% |
| Dyadic International, Inc. | 8.21 Million USD | -5362.004% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1314.414% |
| Fortress Biotech, Inc. | 167.52 Million USD | -167.979% |
| Lantern Pharma Inc. | 43.64 Million USD | -928.544% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -178.259% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -2994.685% |
| Incyte Corporation | 6.78 Billion USD | 93.381% |
| IO Biotech, Inc. | 150.71 Million USD | -197.864% |
| Jaguar Health, Inc. | 50.76 Million USD | -784.374% |
| Novavax, Inc. | 1.85 Billion USD | 75.803% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -18.014% |
| Opthea Limited | 188.79 Million USD | -137.794% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 46.11% |
| ContextLogic Inc. | 423 Million USD | -6.131% |
| MiMedx Group, Inc. | 239.04 Million USD | -87.802% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -158.416% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -8583.965% |
| NextCure, Inc. | 129.41 Million USD | -246.888% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -732.162% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1122.29% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1289.849% |
| Vaxcyte, Inc. | 1.4 Billion USD | 68.114% |
| PDS Biotechnology Corporation | 59.39 Million USD | -655.909% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 29.914% |
| Pharming Group N.V. | 462.85 Million USD | 3.007% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1060.639% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 28.577% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2272.346% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2272.346% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -171.555% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -891.311% |
| Acelyrin, Inc. | 742.69 Million USD | 39.553% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -6715.963% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -6911.323% |
| Summit Therapeutics Inc. | 202.94 Million USD | -121.206% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -503.618% |
| Senti Biosciences, Inc. | 119.48 Million USD | -275.728% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -96.606% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -166.947% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -5333.075% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -9304.206% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 4.317% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -263.06% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -63.279% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 5.056% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -4342.702% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -109.288% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -39552.999% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -8.48% |
| Immix Biopharma, Inc. | 19.92 Million USD | -2153.106% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -21.326% |
| MEI Pharma, Inc. | 41.37 Million USD | -985.039% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1285.345% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -31.731% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -282.969% |
| Fortress Biotech, Inc. | 167.52 Million USD | -167.979% |
| Precigen, Inc. | 151.04 Million USD | -197.223% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1219.698% |
| AlloVir, Inc. | 190.79 Million USD | -135.296% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -19.255% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 11.316% |
| ImmuCell Corporation | 43.8 Million USD | -924.776% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 30.86% |
| Onconetix, Inc. | 88.82 Million USD | -405.435% |
| PureTech Health plc | 693.97 Million USD | 35.309% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -359.574% |
| Elevation Oncology, Inc. | 89.09 Million USD | -403.906% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -7138.552% |
| Seer, Inc. | 436.26 Million USD | -2.903% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -450.186% |
| Innoviva, Inc. | 1.24 Billion USD | 63.898% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -239.016% |
| ESSA Pharma Inc. | 149.12 Million USD | -201.052% |
| GlycoMimetics, Inc. | 45.31 Million USD | -890.666% |
| GT Biopharma, Inc. | 14.1 Million USD | -3081.905% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -45.809% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -85.738% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 4.868% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -785.526% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -371.511% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -70980.356% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 20.731% |
| Aptose Biosciences Inc. | 12.92 Million USD | -3374.045% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -1930.068% |
| Soligenix, Inc. | 9.79 Million USD | -4482.22% |
| Century Therapeutics, Inc. | 360.69 Million USD | -24.465% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -64.959% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -2495.75% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -304.769% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -118.831% |
| Autolus Therapeutics plc | 375.38 Million USD | -19.594% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -78.407% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -26.395% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -813.732% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 32.096% |
| GRI Bio, Inc. | 2.95 Million USD | -15087.246% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -4133.149% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -163.282% |
| IGM Biosciences, Inc. | 423.41 Million USD | -6.028% |
| INmune Bio, Inc. | 57 Million USD | -687.591% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -101.763% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -434.82% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1618.947% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -6422.189% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -496.782% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -204.863% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -171.253% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 28.696% |
| Verastem, Inc. | 149.71 Million USD | -199.854% |
| Abeona Therapeutics Inc. | 64 Million USD | -601.439% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 12.344% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -190.654% |
| Histogen Inc. | 19.07 Million USD | -2253.772% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1882.038% |
| Surrozen, Inc. | 46.08 Million USD | -874.251% |
| Organovo Holdings, Inc. | 6.34 Million USD | -6970.956% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10319.461% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -211.702% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3703.889% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -496.449% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -5169.654% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -23.684% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2381.072% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -4.549% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -3459.665% |
| Apollomics, Inc. | 55.38 Million USD | -710.542% |
| Amarin Corporation plc | 831.68 Million USD | 46.021% |
| Mesoblast Limited | 669.15 Million USD | 32.91% |
| Turnstone Biologics Corp. | 112.81 Million USD | -297.939% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 22.027% |
| Synaptogenix, Inc. | 31.11 Million USD | -1342.887% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -3584.627% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 18.087% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7545.011% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -6011.985% |
| Exelixis, Inc. | 2.94 Billion USD | 84.742% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1856.741% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -23.151% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 43.081% |
| NLS Pharmaceutics AG | 1.84 Million USD | -24210.897% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -5526.715% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -2955.019% |
| Gritstone bio, Inc. | 177.76 Million USD | -152.538% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -370.68% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2413.314% |
| Avid Bioservices, Inc. | 336.55 Million USD | -33.39% |
| Insmed Incorporated | 1.32 Billion USD | 66.241% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -4562.639% |
| MediWound Ltd. | 66.45 Million USD | -575.507% |
| OmniAb, Inc. | 401.98 Million USD | -11.68% |
| Alector, Inc. | 621.82 Million USD | 27.804% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -25.191% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -8247.62% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -691.884% |
| Zai Lab Limited | 1.03 Billion USD | 56.679% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 6.17% |
| Aura Biosciences, Inc. | 255.07 Million USD | -76.001% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 40.144% |
| Immunic, Inc. | 54.29 Million USD | -726.783% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -68.631% |
| Veracyte, Inc. | 1.13 Billion USD | 60.544% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -3697.203% |
| FibroGen, Inc. | 423.52 Million USD | -5.999% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -12679.249% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -9377.991% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -8168.474% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 96.06% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -4998.637% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 13.242% |
| TG Therapeutics, Inc. | 329.58 Million USD | -36.211% |
| Galecto, Inc. | 38.22 Million USD | -1074.392% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1465.543% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 89.697% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -90.708% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1707.161% |
| XBiotech Inc. | 227.24 Million USD | -97.557% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -370.68% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -214.821% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -57.016% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -251.09% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -17.523% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 69.891% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -23.049% |
| Vaxxinity, Inc. | 44.35 Million USD | -912.186% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 13.159% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2312.419% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -47.168% |
| NexImmune, Inc. | 8.59 Million USD | -5123.85% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -4089.706% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -2521.152% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.643% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -1926.691% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -114346.866% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -159.007% |
| Ainos, Inc. | 31.84 Million USD | -1309.892% |
| Pluri Inc. | 39.52 Million USD | -1035.768% |
| Prothena Corporation plc | 696.38 Million USD | 35.533% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -58.85% |
| Celularity Inc. | 143.88 Million USD | -212.001% |
| Rallybio Corporation | 115.62 Million USD | -288.285% |
| Cue Biopharma, Inc. | 61.53 Million USD | -629.62% |
| MeiraGTx Holdings plc | 458.16 Million USD | 2.015% |
| Omeros Corporation | 378.26 Million USD | -18.681% |
| Humacyte, Inc. | 128.22 Million USD | -250.12% |
| Immunocore Holdings plc | 597 Million USD | 24.802% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1336.178% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -555.093% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 57.214% |
| CalciMedica, Inc. | 12.18 Million USD | -3584.325% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -76.99% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -162.676% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -44.336% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 20.585% |
| Pulmatrix, Inc. | 33.95 Million USD | -1222.03% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1553.78% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -218.715% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 65.492% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -244.833% |
| Cytokinetics, Incorporated | 824.31 Million USD | 45.538% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2025.337% |
| Nutriband Inc. | 7.51 Million USD | -5872.141% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -468.603% |
| Vor Biopharma Inc. | 209.82 Million USD | -113.954% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 93.784% |
| Evogene Ltd. | 51.1 Million USD | -778.525% |
| ProKidney Corp. | 420.55 Million USD | -6.749% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -718.731% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -4615.566% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 17.835% |
| CorMedix Inc. | 82.05 Million USD | -447.082% |
| BioLineRx Ltd. | 63.92 Million USD | -602.284% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -11.518% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1491.968% |
| Atai Life Sciences N.V. | 293.47 Million USD | -52.971% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -175.202% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -252.332% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 20.122% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -364.164% |
| MediciNova, Inc. | 66.26 Million USD | -577.433% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -410.455% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -9960.472% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4735.984% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 23.681% |
| Biomea Fusion, Inc. | 199.92 Million USD | -124.549% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 76.411% |
| Mereo BioPharma Group plc | 66.49 Million USD | -575.1% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 7.454% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 26.75% |
| Absci Corporation | 234.48 Million USD | -91.46% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6037.184% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -32.082% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -171.947% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 14.703% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -61.666% |
| Allakos Inc. | 243.61 Million USD | -84.284% |
| Imunon, Inc. | 21.91 Million USD | -1948.242% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -74.212% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 27.768% |
| BioAtla, Inc. | 119.65 Million USD | -275.182% |
| NLS Pharmaceutics AG | 1.84 Million USD | -24210.897% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -13842.081% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 30.163% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -367.957% |
| XOMA Corporation | 234.3 Million USD | -91.606% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -102.922% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -256.739% |
| aTyr Pharma, Inc. | 122.06 Million USD | -267.778% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -191.7% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 22.634% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 8.46% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -306.39% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -2861.79% |
| Akari Therapeutics, Plc | 4.35 Million USD | -10208.496% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2535.007% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 74.099% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -14456.973% |
| UroGen Pharma Ltd. | 178.31 Million USD | -151.771% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 4.631% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -80685.115% |
| Orgenesis Inc. | 14.55 Million USD | -2985.04% |
| Entera Bio Ltd. | 11.76 Million USD | -3715.852% |
| GH Research PLC | 226.3 Million USD | -98.38% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -720.812% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -317.863% |
| Xencor, Inc. | 952.69 Million USD | 52.877% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -5667.577% |
| Replimune Group, Inc. | 487.72 Million USD | 7.953% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -5462.261% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 30.767% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -14456.973% |
| Portage Biotech Inc. | 7.77 Million USD | -5671.115% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -9960.472% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -62.103% |
| OncoCyte Corporation | 74.89 Million USD | -499.443% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -21979.697% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -7658.125% |
| Purple Biotech Ltd. | 44.3 Million USD | -913.352% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1215.522% |
| scPharmaceuticals Inc. | 94.47 Million USD | -375.169% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2387.869% |
| HilleVax, Inc. | 344.43 Million USD | -30.34% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -14035.233% |
| Tharimmune, Inc. | 10.94 Million USD | -4001.214% |
| Genprex, Inc. | 10.67 Million USD | -4107.217% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 9.524% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -366.416% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -18405.153% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -10677.61% |
| OKYO Pharma Limited | 1.54 Million USD | -29027.716% |
| Savara Inc. | 177.56 Million USD | -152.83% |
| Curis, Inc. | 77.28 Million USD | -480.905% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2009.437% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -602.023% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -5452.003% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -2217.562% |
| BeiGene, Ltd. | 5.8 Billion USD | 92.267% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -3589.169% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 78.505% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -25.418% |
| Erasca, Inc. | 395.29 Million USD | -13.569% |
| bluebird bio, Inc. | 619.16 Million USD | 27.493% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10283.916% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 93.438% |
| DBV Technologies S.A. | 182.98 Million USD | -145.338% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10283.916% |
| Moderna, Inc. | 18.42 Billion USD | 97.564% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2364.374% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -3774.806% |
| Molecular Templates, Inc. | 35.38 Million USD | -1168.787% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -224.692% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 43.094% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -47.795% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -331.893% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 3.585% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -43.23% |
| MacroGenics, Inc. | 306.82 Million USD | -46.319% |
| RenovoRx, Inc. | 1.46 Million USD | -30523.124% |
| Adicet Bio, Inc. | 207.29 Million USD | -116.568% |
| Prime Medicine, Inc. | 193.85 Million USD | -131.588% |
| Aditxt, Inc. | 44.57 Million USD | -907.07% |
| Adagene Inc. | 115.72 Million USD | -287.92% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -9978.939% |
| Quantum-Si incorporated | 298.25 Million USD | -50.523% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 69.818% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -5723.425% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -27.799% |
| SciSparc Ltd. | 11.18 Million USD | -3914.801% |
| Vericel Corporation | 353.65 Million USD | -26.941% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3575.996% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -688.981% |
| Generation Bio Co. | 374.75 Million USD | -19.793% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -76.284% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -183.12% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -31.512% |
| Invivyd, Inc. | 229.18 Million USD | -95.887% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 46.807% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -3589.078% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -146.14% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -2098.076% |
| 2seventy bio, Inc. | 565.42 Million USD | 20.602% |
| ADMA Biologics, Inc. | 329.18 Million USD | -36.379% |
| Clene Inc. | 52.34 Million USD | -757.712% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -664.349% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -245.616% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4735.984% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 31.324% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -333.288% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -244.312% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -360.201% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -532.33% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -85.087% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 77.096% |
| Evaxion Biotech A/S | 12.88 Million USD | -3383.189% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -78.106% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 40.356% |
| Trevena, Inc. | 40.6 Million USD | -1005.615% |
| Surrozen, Inc. | 46.08 Million USD | -874.251% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -98.77% |
| Cingulate Inc. | 3.49 Million USD | -12758.176% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -2599.711% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -583.415% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -3742.1% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -67.191% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 40.059% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -256.603% |
| Clearmind Medicine Inc. | 4.32 Million USD | -10281.467% |
| Kronos Bio, Inc. | 213.27 Million USD | -110.492% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -180.964% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5144.194% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -21.831% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2020.65% |
| ImmunityBio, Inc. | 504.45 Million USD | 11.005% |
| Korro Bio, Inc. | 221.66 Million USD | -102.53% |
| Kineta, Inc. | 10.28 Million USD | -4266.647% |
| BioVie Inc. | 25.2 Million USD | -1680.898% |
| Codexis, Inc. | 136.56 Million USD | -228.743% |
| Celularity Inc. | 143.88 Million USD | -212.001% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 29.341% |
| Celcuity Inc. | 191.21 Million USD | -134.775% |
| Virax Biolabs Group Limited | 5.48 Million USD | -8086.315% |
| Cibus, Inc. | 544.41 Million USD | 17.537% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -256.598% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -2085.237% |
| IN8bio, Inc. | 33.7 Million USD | -1231.796% |
| Kodiak Sciences Inc. | 479.37 Million USD | 6.349% |
| Annexon, Inc. | 297.67 Million USD | -50.814% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -159.485% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -226.572% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2038.499% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 84.986% |
| Eyenovia, Inc. | 28.77 Million USD | -1459.919% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -94.742% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6114.493% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -636.853% |
| Arcellx, Inc. | 825.13 Million USD | 45.592% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -449.916% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 2.886% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1359.951% |
| Moolec Science SA | 24.05 Million USD | -1766.574% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -44.759% |
| Geron Corporation | 394.07 Million USD | -13.921% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -341.387% |
| Royalty Pharma plc | 16.38 Billion USD | 97.26% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 24.545% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -6318.111% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -3632.628% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -98.591% |
| Humacyte, Inc. | 128.22 Million USD | -250.12% |
| Structure Therapeutics Inc. | 482.01 Million USD | 6.863% |
| 89bio, Inc. | 596.26 Million USD | 24.709% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -78.041% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -24166.757% |
| Genelux Corporation | 27.89 Million USD | -1509.49% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -402.148% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -95.675% |
| Notable Labs, Ltd. | 19.54 Million USD | -2197.4% |
| Liquidia Corporation | 120.43 Million USD | -272.774% |
| Mustang Bio, Inc. | 17.74 Million USD | -2430.352% |
| Immunovant, Inc. | 666.71 Million USD | 32.664% |
| Quantum-Si incorporated | 298.25 Million USD | -50.523% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -210.895% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -728.905% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -155.736% |
| Acasti Pharma Inc. | 73.3 Million USD | -512.462% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -9761.759% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1618.947% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 53.468% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -8550.137% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1870.655% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -769.978% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -148.455% |
| PepGen Inc. | 143.05 Million USD | -213.826% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1074.7% |
| United Therapeutics Corporation | 7.16 Billion USD | 93.736% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -2240.031% |
| Solid Biosciences Inc. | 164.93 Million USD | -172.182% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7545.011% |
| Immuneering Corporation | 102.58 Million USD | -337.624% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10319.461% |
| Silo Pharma, Inc. | 7.74 Million USD | -5695.596% |
| Belite Bio, Inc | 94.64 Million USD | -374.351% |
| XOMA Corporation | 234.3 Million USD | -91.606% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -92.521% |
| Bionomics Limited | 27.64 Million USD | -1523.688% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -11.841% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -318.05% |
| uniQure N.V. | 831.68 Million USD | 46.021% |
| Cassava Sciences, Inc. | 151.66 Million USD | -196.008% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -9978.939% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -63.914% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1051.706% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -10921.911% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1118.905% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6114.493% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -12679.249% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -3697.775% |
| Altimmune, Inc. | 210.64 Million USD | -113.129% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 42.287% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -318.05% |
| Compugen Ltd. | 121.33 Million USD | -269.999% |
| Peak Bio, Inc. | 2.59 Million USD | -17190.572% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -160.513% |
| Benitec Biopharma Inc. | 52.21 Million USD | -759.864% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -31.322% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1191.045% |
| Zura Bio Limited | 100.84 Million USD | -345.182% |
| PolyPid Ltd. | 15.37 Million USD | -2820.472% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -276.352% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1191.045% |
| Instil Bio, Inc. | 325.63 Million USD | -37.867% |
| argenx SE | 4.54 Billion USD | 90.117% |
| Immunome, Inc. | 148.54 Million USD | -202.232% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -186.174% |
| Verona Pharma plc | 308.12 Million USD | -45.699% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -416.261% |
| Shattuck Labs, Inc. | 159.56 Million USD | -181.351% |
| CervoMed Inc. | 9.97 Million USD | -4401.72% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -138.217% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -3842.176% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -150.236% |
| Moolec Science SA | 24.05 Million USD | -1766.574% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -7238.561% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -159.583% |
| AnaptysBio, Inc. | 452.38 Million USD | 0.764% |
| Design Therapeutics, Inc. | 289.64 Million USD | -54.996% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -516.457% |
| NeurAxis, Inc. | 509.49 Thousand USD | -88013.202% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -8185.991% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1004.717% |
| Achilles Therapeutics plc | 161.45 Million USD | -178.054% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -416.261% |
| 180 Life Sciences Corp. | 5.25 Million USD | -8435.736% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -537.44% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5144.194% |
| Nutriband Inc. | 7.51 Million USD | -5872.141% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -76.27% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -125.255% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -489.061% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -675.148% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 14.739% |
| Palisade Bio, Inc. | 14.05 Million USD | -3094.812% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -113.479% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 69.245% |
| Neurogene Inc. | 222.57 Million USD | -101.702% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 30.572% |
| AEON Biopharma, Inc. | 6.84 Million USD | -6458.583% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 0.905% |
| Sesen Bio, Inc. | 189.17 Million USD | -137.313% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -65.13% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -3174.061% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 42.47% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -68.144% |
| Athira Pharma, Inc. | 160.24 Million USD | -180.155% |
| Vaccinex, Inc. | 3.63 Million USD | -12263.949% |
| HCW Biologics Inc. | 28.51 Million USD | -1474.456% |
| XOMA Corporation | 234.3 Million USD | -91.606% |
| Nektar Therapeutics | 398.03 Million USD | -12.788% |
| Arvinas, Inc. | 1.3 Billion USD | 65.588% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2535.007% |
| Merus N.V. | 458.49 Million USD | 2.085% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -119.672% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -149.126% |
| Rezolute, Inc. | 132.73 Million USD | -238.214% |
| Clene Inc. | 52.34 Million USD | -757.712% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -2908.166% |
| BeyondSpring Inc. | 24.8 Million USD | -1709.638% |
| Synlogic, Inc. | 75.55 Million USD | -494.222% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -3684.648% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -4694.265% |
| Peak Bio, Inc. | 2.59 Million USD | -17190.572% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -156.779% |
| Krystal Biotech, Inc. | 818.35 Million USD | 45.142% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -86.715% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 38.145% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -12449.991% |
| MannKind Corporation | 475.19 Million USD | 5.527% |
| Ikena Oncology, Inc. | 192.09 Million USD | -133.708% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -3256.774% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -285.223% |
| Gossamer Bio, Inc. | 311.91 Million USD | -43.928% |
| CohBar, Inc. | 16.36 Million USD | -2643.151% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1176.726% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6037.184% |
| Legend Biotech Corporation | 1.84 Billion USD | 75.715% |
| Mural Oncology plc | 301.74 Million USD | -48.78% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1338.203% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -7803.222% |
| Disc Medicine, Inc. | 367.99 Million USD | -21.995% |
| Champions Oncology, Inc. | 26.13 Million USD | -1617.951% |
| REGENXBIO Inc. | 573.97 Million USD | 21.784% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -16477.582% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -190.787% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -3617.71% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -32.026% |
| Vaxart, Inc. | 91.83 Million USD | -388.876% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -649.426% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -202.666% |
| Cellectis S.A. | 334.27 Million USD | -34.303% |
| Longeveron Inc. | 12.17 Million USD | -3586.443% |
| Repare Therapeutics Inc. | 253.9 Million USD | -76.815% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 86.248% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -123.521% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 78.505% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -27526.769% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -61.655% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -175.255% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -223.571% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1659.012% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.025% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 61.095% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3575.996% |
| Veru Inc. | 50.59 Million USD | -787.295% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -885.522% |
| Cingulate Inc. | 3.49 Million USD | -12758.176% |
| Passage Bio, Inc. | 150.54 Million USD | -198.207% |
| Context Therapeutics Inc. | 16.06 Million USD | -2694.885% |
| Exicure, Inc. | 11.58 Million USD | -3776.813% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -19.382% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -177.734% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -2469.454% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -34.919% |
| Nuvalent, Inc. | 732.38 Million USD | 38.702% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -2904.099% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -401.301% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -3063.519% |
| OmniAb, Inc. | 401.98 Million USD | -11.68% |
| Anew Medical, Inc. | 19.45 Million USD | -2207.443% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1579.734% |
| Lipocine Inc. | 23 Million USD | -1851.8% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -221.111% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -46.92% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -434.82% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -269.372% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -5557.656% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 49.116% |
| Ocugen, Inc. | 64.54 Million USD | -595.516% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -260.472% |
| Q32 Bio Inc. | 306.11 Million USD | -46.654% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -10568.607% |
| Alumis Inc. Common Stock | 89.61 Million USD | -400.976% |
| Equillium, Inc. | 50.53 Million USD | -788.452% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -497.028% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -987.707% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -26294.697% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1617.36% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -596.661% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -11945.114% |
| Dominari Holdings Inc. | 57.55 Million USD | -679.97% |
| Edesa Biotech, Inc. | 8.89 Million USD | -4949.639% |
| vTv Therapeutics Inc. | 11.01 Million USD | -3974.56% |
| Bio-Techne Corporation | 2.81 Billion USD | 84.042% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 52.094% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 44.675% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -61.682% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -976.531% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 32.753% |
| Nkarta, Inc. | 378.88 Million USD | -18.488% |
| BioCardia, Inc. | 2.98 Million USD | -14929.628% |
| Iterum Therapeutics plc | 26.25 Million USD | -1609.642% |